A Study of LY2216684 and Theophylline in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01263106
First received: December 16, 2010
Last updated: March 15, 2011
Last verified: March 2011

December 16, 2010
March 15, 2011
December 2010
January 2011   (final data collection date for primary outcome measure)
  • Pharmacokinetics, concentration maximum (Cmax) of Theophylline [ Time Frame: Predose 1,2,3,4,6,8,12,24,48,and 72 hours post administration of theophylline on days 1 and 3. ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics, time to concentration maximum (tmax) of Theophylline [ Time Frame: Predose 1,2,3,4,6,8,12,24,48,and 72 hours post administration of theophylline on days 1 and 3. ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics, area under the curve (AUC) of Theophylline [ Time Frame: Predose 1,2,3,4,6,8,12,24,48,and 72 hours post administration of theophylline on days 1 and 3. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01263106 on ClinicalTrials.gov Archive Site
Change in Heart Rate [ Time Frame: Baseline, day 1 and day 3 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
A Study of LY2216684 and Theophylline in Healthy Subjects
Effect of LY2216684 on the Pharmacokinetics of Theophylline in Healthy Subjects

The primary aim of this study is to confirm that LY2216684 is not an inhibitor of CYP1A2 in vivo using theophylline as a probe substrate for the enzyme. Since LY2216684 has been observed to increase heart rate in some healthy subjects, this study will also assess heart rate when co-administered with theophylline.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: LY2216684
    Administered orally
  • Drug: Theophylline
    administered orally
  • Experimental: Theophylline,LY2216684+Theophylline
    Single dose of 200 mg Theophylline on Day 1 in period 1. 18 mg LY2216684 once daily (QD) on Days 1 to 5, with a single dose of 200 mg theophylline co-administered on Day 3 in period 2. There is a washout period of at least 7 days between dosing periods.
    Interventions:
    • Drug: LY2216684
    • Drug: Theophylline
  • Experimental: LY2216684+Theophylline, Theophylline
    18 mg LY2216684 once daily (QD) on Days 1 to 5, with a single dose of 200 mg theophylline co-administered on Day 3 in period 1. Single dose of 200 mg Theophylline on Day 1 in period 2. There is a washout period of at least 7 days between dosing periods.
    Interventions:
    • Drug: LY2216684
    • Drug: Theophylline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are overtly healthy males or females, as determined by medical history and physical examination.
  • Male subjects - Agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.
  • Female subjects - Are women of child-bearing potential who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or Women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone (FSH) >40 mIU/mL).
  • Have body weight >50 kg.
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
  • Have venous access sufficient to allow blood sampling as per the protocol.
  • Have normal sitting blood pressure and pulse rate as determined by the investigator.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion Criteria:

  • Are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to LY2216684, theophylline, or related compounds.
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening.
  • Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have a history or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation.
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.
  • Show evidence of hepatitis C and/or positive hepatitis C antibody.
  • Show evidence of hepatitis B and/or positive hepatitis B surface antigen.
  • Are women with a positive pregnancy test or women who are lactating.
  • Intend to use over-the-counter or prescription medication within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor.
  • Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of CYP1A2 within 30 days prior to dosing.
  • Have donated blood of more than 500 mL within the last month.
  • Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption for 48 hours prior to check-in in each period and while resident at the CRU (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine and chocolate restrictions.
  • Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
  • Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
  • Have a documented or suspected history of glaucoma.
  • Subjects determined to be unsuitable by the investigator for any reason.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01263106
12594, H9P-EW-LNCE
No
Chief Medical Officer, Eli Lilly
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP